These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8049119)

  • 1. Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient.
    Pool JL
    Br J Clin Pract Suppl; 1994 May; 74():8-12. PubMed ID: 8049119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond blood pressure control. Effect of antihypertensive therapy on cardiovascular risk factors.
    Maxwell MH
    Am J Hypertens; 1988 Oct; 1(4 Pt 2):366S-371S. PubMed ID: 3056446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension and CHD risk: whither alpha-1 blockers?
    Pandit RB
    Indian Heart J; 1996; 48(3):265-71. PubMed ID: 8755013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxazosin: a new approach to hypertension and benign prostatic hyperplasia.
    Pool JL
    Br J Clin Pract; 1996; 50(3):154-63. PubMed ID: 8733335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive drug therapy and coronary heart disease risk.
    Schoenberger JA
    J Fam Pract; 1993 Jan; 36(1):70-3, 77-84. PubMed ID: 8419507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Doxazosin (alpha 1-adrenoreceptor antagonist) used in primary hypertension and it's beneficial effect on lipid metabolism].
    Sznajderman M; Chotkowska E; Peczkowska M; Sawicki M; Janaszek-Sitkowska H; Wiernikowska-Wegorek I; Galewicz A; Cybulska I
    Kardiol Pol; 1993 Feb; 38(2):107-11. PubMed ID: 8230980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters.
    Zehetgruber M; Christ G; Gabriel H; Mundigler G; Beckmann R; Binder BR; Huber K
    Thromb Haemost; 1998 Feb; 79(2):378-82. PubMed ID: 9493594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classical risk factors and emerging elements in the risk profile for coronary artery disease.
    Gensini GF; Comeglio M; Colella A
    Eur Heart J; 1998 Feb; 19 Suppl A():A53-61. PubMed ID: 9519344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Haywood LJ; Ford CE; Crow RS; Davis BR; Massie BM; Einhorn PT; Williard A;
    J Am Coll Cardiol; 2009 Nov; 54(22):2023-31. PubMed ID: 19926008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term organ protection by doxazosin and/or quinapril as antihypertensive therapy.
    Gallego-Delgado J; Lazaro A; Gomez-Garre D; Osende JI; Gonzalez-Rubio ML; Herraiz M; Manzarbeitia F; Fortes J; Fernandez-Cruz A; Egido J
    J Nephrol; 2006; 19(5):588-98. PubMed ID: 17136686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy.
    Ikeda T; Gomi T; Shibuya Y; Shinozaki S; Suzuki Y; Matsuda N
    Hypertens Res; 2007 Nov; 30(11):1097-105. PubMed ID: 18250559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic and cardiovascular characteristics of hypertension. Familial aspects.
    Neutel JM; Smith DH
    Cardiol Clin; 1995 Nov; 13(4):539-47. PubMed ID: 8565017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of multiple risk factors on the hazard of hypertension.
    Kannel WB
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S53-7. PubMed ID: 11527137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
    Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renal and cardiac effects of chronic doxazosin therapy in patients with essential arterial hypertension].
    Bignotti M; Lamponi M
    Minerva Cardioangiol; 1996 Jun; 44(6):331-5. PubMed ID: 8927264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reducing blood pressure and modification of coronary risk factors by therapy with doxazosin].
    Hitzenberger G; Ganzinger U
    Wien Klin Wochenschr; 1993; 105(13):371-6. PubMed ID: 8351927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary disease in hypertension: a new mosaic.
    Julius S
    J Hypertens Suppl; 1997 Mar; 15(2):S3-10. PubMed ID: 9218191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha 1 blockers: antihypertensives whose positive metabolic profile with regard to hyperinsulinaemia and lipid metabolism cannot be ignored.
    Waite MA
    J Intern Med Suppl; 1991; 735():113-7. PubMed ID: 1675053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.